Cargando…

Optimized Inhibitors of MDM2 via an Attempted Protein‐Templated Reductive Amination

Innovative and efficient hit‐identification techniques are required to accelerate drug discovery. Protein‐templated fragment ligations represent a promising strategy in early drug discovery, enabling the target to assemble and select its binders from a pool of building blocks. Development of new pro...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Vlag, Ramon, Yagiz Unver, M., Felicetti, Tommaso, Twarda‐Clapa, Aleksandra, Kassim, Fatima, Ermis, Cagdas, Neochoritis, Constantinos G., Musielak, Bogdan, Labuzek, Beata, Dömling, Alexander, Holak, Tad A., Hirsch, Anna K. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064911/
https://www.ncbi.nlm.nih.gov/pubmed/31774938
http://dx.doi.org/10.1002/cmdc.201900574
_version_ 1783504957728620544
author van der Vlag, Ramon
Yagiz Unver, M.
Felicetti, Tommaso
Twarda‐Clapa, Aleksandra
Kassim, Fatima
Ermis, Cagdas
Neochoritis, Constantinos G.
Musielak, Bogdan
Labuzek, Beata
Dömling, Alexander
Holak, Tad A.
Hirsch, Anna K. H.
author_facet van der Vlag, Ramon
Yagiz Unver, M.
Felicetti, Tommaso
Twarda‐Clapa, Aleksandra
Kassim, Fatima
Ermis, Cagdas
Neochoritis, Constantinos G.
Musielak, Bogdan
Labuzek, Beata
Dömling, Alexander
Holak, Tad A.
Hirsch, Anna K. H.
author_sort van der Vlag, Ramon
collection PubMed
description Innovative and efficient hit‐identification techniques are required to accelerate drug discovery. Protein‐templated fragment ligations represent a promising strategy in early drug discovery, enabling the target to assemble and select its binders from a pool of building blocks. Development of new protein‐templated reactions to access a larger structural diversity and expansion of the variety of targets to demonstrate the scope of the technique are of prime interest for medicinal chemists. Herein, we present our attempts to use a protein‐templated reductive amination to target protein‐protein interactions (PPIs), a challenging class of drug targets. We address a flexible pocket, which is difficult to achieve by structure‐based drug design. After careful analysis we did not find one of the possible products in the kinetic target‐guided synthesis (KTGS) approach, however subsequent synthesis and biochemical evaluation of each library member demonstrated that all the obtained molecules inhibit MDM2. The most potent library member (K (i)=0.095 μm) identified is almost as active as Nutlin‐3, a potent inhibitor of the p53‐MDM2 PPI.
format Online
Article
Text
id pubmed-7064911
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-70649112020-03-16 Optimized Inhibitors of MDM2 via an Attempted Protein‐Templated Reductive Amination van der Vlag, Ramon Yagiz Unver, M. Felicetti, Tommaso Twarda‐Clapa, Aleksandra Kassim, Fatima Ermis, Cagdas Neochoritis, Constantinos G. Musielak, Bogdan Labuzek, Beata Dömling, Alexander Holak, Tad A. Hirsch, Anna K. H. ChemMedChem Full Papers Innovative and efficient hit‐identification techniques are required to accelerate drug discovery. Protein‐templated fragment ligations represent a promising strategy in early drug discovery, enabling the target to assemble and select its binders from a pool of building blocks. Development of new protein‐templated reactions to access a larger structural diversity and expansion of the variety of targets to demonstrate the scope of the technique are of prime interest for medicinal chemists. Herein, we present our attempts to use a protein‐templated reductive amination to target protein‐protein interactions (PPIs), a challenging class of drug targets. We address a flexible pocket, which is difficult to achieve by structure‐based drug design. After careful analysis we did not find one of the possible products in the kinetic target‐guided synthesis (KTGS) approach, however subsequent synthesis and biochemical evaluation of each library member demonstrated that all the obtained molecules inhibit MDM2. The most potent library member (K (i)=0.095 μm) identified is almost as active as Nutlin‐3, a potent inhibitor of the p53‐MDM2 PPI. John Wiley and Sons Inc. 2019-12-12 2020-02-17 /pmc/articles/PMC7064911/ /pubmed/31774938 http://dx.doi.org/10.1002/cmdc.201900574 Text en © 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Full Papers
van der Vlag, Ramon
Yagiz Unver, M.
Felicetti, Tommaso
Twarda‐Clapa, Aleksandra
Kassim, Fatima
Ermis, Cagdas
Neochoritis, Constantinos G.
Musielak, Bogdan
Labuzek, Beata
Dömling, Alexander
Holak, Tad A.
Hirsch, Anna K. H.
Optimized Inhibitors of MDM2 via an Attempted Protein‐Templated Reductive Amination
title Optimized Inhibitors of MDM2 via an Attempted Protein‐Templated Reductive Amination
title_full Optimized Inhibitors of MDM2 via an Attempted Protein‐Templated Reductive Amination
title_fullStr Optimized Inhibitors of MDM2 via an Attempted Protein‐Templated Reductive Amination
title_full_unstemmed Optimized Inhibitors of MDM2 via an Attempted Protein‐Templated Reductive Amination
title_short Optimized Inhibitors of MDM2 via an Attempted Protein‐Templated Reductive Amination
title_sort optimized inhibitors of mdm2 via an attempted protein‐templated reductive amination
topic Full Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064911/
https://www.ncbi.nlm.nih.gov/pubmed/31774938
http://dx.doi.org/10.1002/cmdc.201900574
work_keys_str_mv AT vandervlagramon optimizedinhibitorsofmdm2viaanattemptedproteintemplatedreductiveamination
AT yagizunverm optimizedinhibitorsofmdm2viaanattemptedproteintemplatedreductiveamination
AT felicettitommaso optimizedinhibitorsofmdm2viaanattemptedproteintemplatedreductiveamination
AT twardaclapaaleksandra optimizedinhibitorsofmdm2viaanattemptedproteintemplatedreductiveamination
AT kassimfatima optimizedinhibitorsofmdm2viaanattemptedproteintemplatedreductiveamination
AT ermiscagdas optimizedinhibitorsofmdm2viaanattemptedproteintemplatedreductiveamination
AT neochoritisconstantinosg optimizedinhibitorsofmdm2viaanattemptedproteintemplatedreductiveamination
AT musielakbogdan optimizedinhibitorsofmdm2viaanattemptedproteintemplatedreductiveamination
AT labuzekbeata optimizedinhibitorsofmdm2viaanattemptedproteintemplatedreductiveamination
AT domlingalexander optimizedinhibitorsofmdm2viaanattemptedproteintemplatedreductiveamination
AT holaktada optimizedinhibitorsofmdm2viaanattemptedproteintemplatedreductiveamination
AT hirschannakh optimizedinhibitorsofmdm2viaanattemptedproteintemplatedreductiveamination